JP5780954B2 - ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類 - Google Patents

ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類 Download PDF

Info

Publication number
JP5780954B2
JP5780954B2 JP2011507892A JP2011507892A JP5780954B2 JP 5780954 B2 JP5780954 B2 JP 5780954B2 JP 2011507892 A JP2011507892 A JP 2011507892A JP 2011507892 A JP2011507892 A JP 2011507892A JP 5780954 B2 JP5780954 B2 JP 5780954B2
Authority
JP
Japan
Prior art keywords
cyclobutyl
carbonyl
azetidin
oxy
diazepan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011507892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519891A (ja
JP2011519891A5 (cg-RX-API-DMAC10.html
Inventor
アダム・ジェイムズ・ダベンポート
デイヴィッド・ジェイムズ・ハレット
マッスィーモ・コルスィ
Original Assignee
エヴォテック・アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヴォテック・アクチエンゲゼルシャフト filed Critical エヴォテック・アクチエンゲゼルシャフト
Publication of JP2011519891A publication Critical patent/JP2011519891A/ja
Publication of JP2011519891A5 publication Critical patent/JP2011519891A5/ja
Application granted granted Critical
Publication of JP5780954B2 publication Critical patent/JP5780954B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011507892A 2008-05-08 2009-05-05 ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類 Expired - Fee Related JP5780954B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08155915.5 2008-05-08
EP08155915 2008-05-08
US13946108P 2008-12-19 2008-12-19
US61/139,461 2008-12-19
PCT/EP2009/055418 WO2009135842A1 (en) 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine h3 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2011519891A JP2011519891A (ja) 2011-07-14
JP2011519891A5 JP2011519891A5 (cg-RX-API-DMAC10.html) 2012-05-10
JP5780954B2 true JP5780954B2 (ja) 2015-09-16

Family

ID=39720542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507892A Expired - Fee Related JP5780954B2 (ja) 2008-05-08 2009-05-05 ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類

Country Status (9)

Country Link
US (1) US8691804B2 (cg-RX-API-DMAC10.html)
EP (1) EP2300422B1 (cg-RX-API-DMAC10.html)
JP (1) JP5780954B2 (cg-RX-API-DMAC10.html)
CN (1) CN102015636B (cg-RX-API-DMAC10.html)
BR (1) BRPI0913057A2 (cg-RX-API-DMAC10.html)
CA (1) CA2721303C (cg-RX-API-DMAC10.html)
IL (1) IL208613A (cg-RX-API-DMAC10.html)
TW (1) TWI454468B (cg-RX-API-DMAC10.html)
WO (1) WO2009135842A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
EP2391617B1 (en) 2009-02-02 2015-11-11 Evotec AG Azetidines as histamine h3 receptor antagonists
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CN102471235A (zh) * 2009-07-11 2012-05-23 拜耳医药股份有限公司 利用环烷基的放射性标记方法
AU2011218491C1 (en) 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
EA201291384A1 (ru) * 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
EA023260B1 (ru) 2011-02-23 2016-05-31 Сувен Лайф Сайенсиз Лимитед Новые соединения в качестве лигандов гистаминовых h-рецепторов
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CA2878217C (en) 2012-08-23 2016-05-17 Suven Life Sciences Limited Acrylamide compounds as histamine h3 receptor ligands
EP2905276A4 (en) * 2012-09-05 2016-03-09 Zhejiang Hisun Pharm Co Ltd CRYSTALLINE FORMS OF AZETIDINONE COMPOUNDS AND MANUFACTURING METHOD
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN112279809A (zh) * 2020-09-23 2021-01-29 山东省海洋化工科学研究院 一种2-氰基-4-氟吡啶的制备方法
CN115073276A (zh) * 2022-07-15 2022-09-20 济南大学 一种泊沙康唑主环杂质的制备及控制方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
ZA861210B (en) 1985-02-28 1987-10-28 Robins Co Inc A H 3-aryloxyazetidinecarboxamides as anticonvulsants and antiepileptics
US6559140B2 (en) * 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
DE10150310A1 (de) 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
US20080045506A1 (en) 2004-10-15 2008-02-21 Glaxo Group Limited Pyrrolidine Derivatives as Histamine Receptors Ligands
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
BRPI0707916A2 (pt) 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
US8106208B2 (en) * 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
CN105712977B (zh) * 2007-11-20 2021-06-29 詹森药业有限公司 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Also Published As

Publication number Publication date
CN102015636B (zh) 2014-08-13
IL208613A (en) 2015-07-30
EP2300422A1 (en) 2011-03-30
IL208613A0 (en) 2010-12-30
US8691804B2 (en) 2014-04-08
JP2011519891A (ja) 2011-07-14
BRPI0913057A2 (pt) 2015-10-13
TWI454468B (zh) 2014-10-01
TW201006820A (en) 2010-02-16
WO2009135842A1 (en) 2009-11-12
CA2721303A1 (en) 2009-11-12
US20110105459A1 (en) 2011-05-05
EP2300422B1 (en) 2014-11-05
CA2721303C (en) 2016-06-28
CN102015636A (zh) 2011-04-13
HK1155749A1 (en) 2012-05-25

Similar Documents

Publication Publication Date Title
US8691804B2 (en) Azetidines and cyclobutanes as histamine H3 receptor antagonists
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
KR102049534B1 (ko) 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
AU2008341352B2 (en) Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
TWI583685B (zh) Ｒｏｒｃ２的經甲基及三氟甲基取代之吡咯並吡啶調節劑及其使用方法
KR20190067923A (ko) 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
JP2021193099A (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
EA028722B1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
JP2021518340A (ja) Ｏ−糖タンパク質−２−アセトアミド−２−デオキシ−３−ｄ−グリコピラノシダーゼ阻害剤
WO2022152852A1 (en) Antagonists of mrgx2
JP2023545065A (ja) オートタキシン抑制剤化合物
TWI449700B (zh) 作為組織胺ｈ３受體拮抗劑之三亞甲亞胺類
WO2017018475A1 (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
JP7678756B2 (ja) アゼパン誘導体
KR20080050569A (ko) 대사성 글루타메이트 수용체 길항제로서 아세틸렌성피페라진
WO2019013562A1 (ko) 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
KR20080050392A (ko) 대사성 글루타메이트 수용체 길항제로서 바이시클릭피페라진
JP2023537586A (ja) Ｃｄｋ９阻害剤およびその使用
EP4211118A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
KR20190132703A (ko) 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
WO2024149728A1 (en) Substituted (hetero)anilines and their use
HK1155749B (en) Azetidines and cyclobutanes as histamine h3 receptor antagonists
HK40039990B (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK1234388A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 an methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150714

R150 Certificate of patent or registration of utility model

Ref document number: 5780954

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees